Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by UroGen Pharma Ltd.

< Previous 1 2 3 4 5 6 Next >
News headline image
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
News headline image
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.